HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EFSA's Lower Safe Intake Level For Selenium Stands Despite Supplement Industry’s Objections

Executive Summary

The European Food Safety Authority has rejected a request from industry association Food Supplements Europe to apply its new lower intake limit for selenium to only selenomethionine and not other forms authorized for use in supplements.

You may also be interested in...



EU’s Proposed Safe Limit For Vitamin B6 In Supplements 8 Times Lower Than US Cap

EFSA has halved its tolerable upper intake level for vitamin B6 in supplements to 12mg/day, a limit more than eight times lower than the cap set by the US and the World Health Organization. Hylobates Consulting's Luca Bucchini expects that this lower UL will push the EU to set a maximum permitted level for vitamin B6 in supplements which is "massively lower" than currently applied by some member states.

People On The Move: Appointments At Orkla, PAGB, Afepadi

A round-up of the latest appointments in Europe's consumer health industry: Orkla Health names BioGaia's Ducellier as its CEO; PAGB makes changes to its board; and Afepadi names Uriach's Gispert as its president.

Germany's Dermapharm Looks To Future With Arkopharma As 2022 Sales Rise

Dermapharm has high hopes for 2023 as its acquisition of Arkopharma means the firm is now the number-one and number-three player respectively in the French and Spanish supplements markets.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS153353

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel